>Mentor is developing the anti-wrinkle injection PurTox, which would compete with Irvine, Calif.-based Allergan's Botox.<
This is somewhat misleading insofar as PurTox is being developed for both cosmetic and medical applications. 50% of worldwide Botox sales come from non-cosmetic indications.
PurTox is the main driver of the JNJ buyout, IMO, although I expect the reports in the business press to miss this point because PurTox is not yet on the market. The breast-implant business is but a modest grower and MNT’s dermal fillers are commodity products. PurTox, on the other hand, has a bona fide chance to be a mega-blockbuster in the right hands because it is technically superiority to Botox. MNT was hardly the ideal company to exploit this opportunity, especially in non-cosmetic indications.
I first mentioned PurTox on this board five years ago when MNT licensed it from the University of Wisconsin and it didn’t yet have a brand name: #msg-1936203. Now, the phase-3 clinical trials for cosmetic use are almost done.
Despite a 92% premium to the market price, the $1.1B buyout price (including net debt) makes this is a great pick-up for JNJ. PurTox alone is worth almost that much, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.